Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study
Bart Maes(KU Leuven), Yves Vanrenterghem, Johan Vanwalleghem(KU Leuven), Kathleen Claes, Pieter Evenepoel(FIND), Raymond Oyen(KU Leuven), Boudewijn Van Damme(KU Leuven), Dirk Kuypers(Stanford University)
Cited by 263
Related Papers
Calcineurin Inhibitor Nephrotoxicity
|Clinical Journal of the American Society of Nephrology|2009|1.5k
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
|New England Journal of Medicine|2004|1.1k
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
|Kidney International|2017|998
Uremic toxins originating from colonic microbial metabolism
|Kidney International|2009|442
Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target
|American Journal of Kidney Diseases|2015|387